<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03373825</url>
  </required_header>
  <id_info>
    <org_study_id>1612001662</org_study_id>
    <nct_id>NCT03373825</nct_id>
  </id_info>
  <brief_title>Rapid Self-Testing to Prevent Fentanyl Overdose Among Young People Who Use Drugs</brief_title>
  <acronym>RAPiDS2</acronym>
  <official_title>Rapid Self-Testing to Prevent Fentanyl Overdose Among Young People Who Use Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research team will enroll 100 young adults who use cocaine, heroin, inject drugs, or
      purchase prescription medications on the illicit market in a pilot study to be known as the
      Rhode Island Young Adult Prescription and Illicit Drug Study (RAPIDS). Participants will be
      trained to use a take-home home rapid drug test to test for the presence or absence of
      fentanyl in their drug supply. Half of the enrolled participants will be asked to test their
      urine for presence or absence of fentanyl, and the other half will be asked to test their
      drug residue for presence or absence of fentanyl. All participants will receive up to 15
      take-home rapid drug tests for fentanyl. A follow-up survey will examine and compare
      utilization of the tests between the two groups. The study will be guided by the
      information-motivation-behavioral skills (IMB) model of engagement in health behaviors. The
      IMB model hypothesizes that if a person possesses the information, motivation, and behavioral
      skills to act, there is an increased likelihood that she/he will fulfill and maintain the
      desired behaviors (behaviors that will reduce accidental overdose).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research team will administer a brief survey to ascertain behavioral, psychosocial, and
      clinical factors that may be related to non-prescription fentanyl (NPF) exposure among young
      people who use illicit drugs. The researchers will also characterize knowledge of and
      perceptions towards drugs contaminated with NPF, as well as the potential diversion of
      prescription fentanyl formulations (e.g., transdermal patches). After the
      interviewer-administered survey has been completed, participants will provide urine samples
      to determine recent exposure to NPF and other illicit drugs.

      The research team will assess the acceptability and feasibility of &quot;take home rapid drug
      tests&quot; to test for fentanyl exposure among 100 participants from the target population. After
      the enrollment and baseline survey, participants will be provided with rapid drug tests that
      detect the presence or absence of fentanyl in their drug supply. Half the participants will
      be asked to test their urine to see if they have been exposed to a fentanyl-contaminated
      drug. The other half will be asked to test the residue of the drug that they intend to use.
      Study participants will then be asked to return in 2 weeks for a brief follow-up survey that
      will assess whether they used the self-tests, whether the technology was acceptable and easy
      to use, and whether and how a positive test result altered their drug-using and overdose
      prevention behaviors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Actual">December 15, 2017</completion_date>
  <primary_completion_date type="Actual">October 18, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be assigned to either ARM1 or ARM2 depending on when they enrolled in the study.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants in ARM1 were only aware of the use of the &quot;Take home rapid drug test&quot; as a urine test. Participants in ARM2, while instructed to test their drug residue, were aware of the ability to use the &quot;take home rapid drug test&quot; as a urine test.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Willingness to use the take-home rapid drug test</measure>
    <time_frame>At 2 week follow-up</time_frame>
    <description>Self-reported measure of willingness to use take-home rapid drug tests (compare Arm1 and Arm2), measured by response to Likert-scale survey question (Strongly Agree--Strongly Disagree).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Current overdose prevention behaviors</measure>
    <time_frame>At baseline enrollment</time_frame>
    <description>Self-reported steps taken to avoid accidental overdose, measured by a &quot;check all that apply&quot; survey question (what they do to avoid an accidental overdose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of take-home rapid drug tests conducted</measure>
    <time_frame>At 2 week follow-up</time_frame>
    <description>Self-reported number of take home rapid drug tests used by participant (Arm1 vs Arm2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in overdose prevention behaviors</measure>
    <time_frame>At 2 week follow-up</time_frame>
    <description>Self-reported actions taken in response to the take home rapid drug test results, measured by a &quot;check all that apply&quot; survey question (what they did after they found out the drugs were laced with fentanyl).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recent non-prescription fentanyl exposure</measure>
    <time_frame>At baseline enrollment</time_frame>
    <description>Self-reported from personal experience (belief that they had ever been exposed to fentanyl), measured by Likert-Scale survey question (Strongly Agree--Strongly Disagree).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recent non-prescription fentanyl exposure</measure>
    <time_frame>At 2 week follow-up.</time_frame>
    <description>Self-reported measure from take home rapid drug test results (any positive result).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of take home drug tests reporting the presence of fentanyl exposure</measure>
    <time_frame>At 2 week follow-up</time_frame>
    <description>Self-reported measure of the number of times they received a positive rapid drug test result.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Accidental Overdose of Opiate</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 participants will receive a kit containing 10 Rapid Response fentanyl test strips. We will ask participants to use the take-home rapid drug test to test their urine for presence or absence of fentanyl.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 participants will receive a kit containing 10 Rapid Response fentanyl test strips. We will ask the participants to use the take-home rapid drug test to test the residue of their drug (ie. instruct them to test bags, cookers, spoons, etc.) for the presence or absence of fentanyl.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Take home rapid drug test</intervention_name>
    <description>The Rapid Response fentanyl test strips will be offered as take-home rapid drug tests to all participants to assess the willingness to use take-home rapid drug tests and the feasibility of using such an intervention at home. Arm 1 will be offered one method of using the take-home rapid drug test (urine testing). Arm 2 will be offered a second method of using the take-home rapid drug test (testing drug residue).</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Rapid Response fentanyl test strips</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  18-35 years of age

          -  resident of Rhode Island

          -  able to complete interviews in English

          -  self-reported heroin, cocaine, injection drug use, or counterfeit prescription pill
             use in the past 30 days

        Exclusion Criteria

        -participants who exclusively misuse medications obtained from a physician or diversion
        from someone else's prescription
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brandon DL Marshall, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Amlani A, McKee G, Khamis N, Raghukumar G, Tsang E, Buxton JA. Why the FUSS (Fentanyl Urine Screen Study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada. Harm Reduct J. 2015 Nov 14;12:54. doi: 10.1186/s12954-015-0088-4.</citation>
    <PMID>26577516</PMID>
  </reference>
  <reference>
    <citation>BTNX Inc. Rapid Reponseâ„¢ Multi-Drug Integrated Split Specimen Cup. 2016 [cited 2016 Sept 18]; Available from: http://www.btnx.com/Product.aspx?id=18240</citation>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>overdose prevention</keyword>
  <keyword>opioid overdose</keyword>
  <keyword>risk behavior</keyword>
  <keyword>harm reduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug Overdose</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

